Bayer receives approval of EYLEA® for second indication in Europe

Bayer HealthCare has announced that EYLEA (aflibercept solution for injection, known in the scientific literature as VEGF Trap-Eye) has been approved by the European Commission for the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO)...

Full Story →